Literature DB >> 21255697

Production of recombinant human HMGB1 and anti-HMGB1 rabbit serum.

Qing Lin1, Jiazhu Fang, Dan Fang, Bing Li, Hongyan Zhou, Shao Bo Su.   

Abstract

High-mobility group box-1 (HMGB1) plays important roles in inflammation, immune responses, and tumor progression. Since HMGB1 and its components have been shown to be mediators of a number of diseases but several sources of recombinant HMGB1 showed controversial biological activity, it is important to obtain recombinant HMGB1 with properties that resemble the native protein. For this purpose, we cloned genes coding for human HMGB1 and its active components A box and B box by PCR and inserted the cloned genes into pET28a vectors for transformation of Escherichia coli BL21. The E. coli expressed proteins were then purified with a Ni(2+)-NTA column and the endotoxin content was removed. Recombinant human HMGB1 (rhHMGB1) and its B box thus obtained stimulated, but A box inhibited, the production of the chemokine CXCL8/IL-8 by THP-1 monocytic cell line. We also used purified rhHMGB1 to immunize rabbits and generated potent anti-sera, which was capable of neutralizing the activity of rhHMGB1 in vitro and detecting the increased HMGB1 expression in inflammatory tissues in mice and humans. Thus, we have established essential means to produce biologically active rhHMGB1 that will facilitate us to study its role in diseases and to explore its potential as a therapeutic agent.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21255697     DOI: 10.1016/j.intimp.2011.01.005

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

1.  RELMα Licenses Macrophages for Damage-Associated Molecular Pattern Activation to Instigate Pulmonary Vascular Remodeling.

Authors:  Qing Lin; Chunling Fan; John T Skinner; Elizabeth N Hunter; Andrew A Macdonald; Peter B Illei; Kazuyo Yamaji-Kegan; Roger A Johns
Journal:  J Immunol       Date:  2019-10-14       Impact factor: 5.422

Review 2.  Exploring the role of high-mobility group box 1 (HMGB1) protein in the pathogenesis of Huntington's disease.

Authors:  Efthalia Angelopoulou; Yam Nath Paudel; Christina Piperi
Journal:  J Mol Med (Berl)       Date:  2020-02-08       Impact factor: 4.599

3.  High-mobility group box-1 mediates toll-like receptor 4-dependent angiogenesis.

Authors:  Qing Lin; Xiao Ping Yang; Dan Fang; Xiangrong Ren; Hongyan Zhou; Jiazhu Fang; Xialin Liu; Shiyou Zhou; Feng Wen; Xiaohong Yao; Ji Ming Wang; Shao Bo Su
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-03-03       Impact factor: 8.311

4.  Toll-like receptor 4 on islet β cells senses expression changes in high-mobility group box 1 and contributes to the initiation of type 1 diabetes.

Authors:  Min Li; Lujun Song; Xiaodong Gao; Wenju Chang; Xinyu Qin
Journal:  Exp Mol Med       Date:  2012-04-30       Impact factor: 8.718

5.  Vitexin alleviates lipopolysaccharide‑induced islet cell injury by inhibiting HMGB1 release.

Authors:  Feifei Wang; Jiajing Yin; Yujin Ma; Hongwei Jiang; Yanbo Li
Journal:  Mol Med Rep       Date:  2017-01-12       Impact factor: 2.952

6.  Antibodies against High Mobility Group Box protein-1 (HMGB1) versus other anti-nuclear antibody fine-specificities and disease activity in systemic lupus erythematosus.

Authors:  Lina Wirestam; Hanna Schierbeck; Thomas Skogh; Iva Gunnarsson; Lars Ottosson; Helena Erlandsson-Harris; Jonas Wetterö; Christopher Sjöwall
Journal:  Arthritis Res Ther       Date:  2015-11-23       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.